The pharmacological properties, experimental research and clinical application of tafluprost
Abstract
Pharmacodynamics of tafluprost, the first commercially available preservative-free unit-dose prostaglandin analogue, is analyzed in the article. Characteristic of the experimental pre-clinical studies, as well as the first three phases of tafluprost clinical trials are presented. A strong IOP-lowering effect of a once a day local administration of tafluprost in the patients with ocular hypertension and primary open-angle glaucoma is described. The review also analyzes post-approval studies of the comparative efficacy and tolerability of tafluprost and assesses the prospects of the new drug.
About the Authors
S. Yu. Petrov
Scientific Research Institute of Eye Diseases
Russian Federation
Russian Federation
D. M. Safonova
Scientific Research Institute of Eye Diseases
Russian Federation
Russian Federation
References
1. Brasnu E., Brignole-Baudouin F., Riancho L. [et al.] In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line // Current Eye Research. 2008. Vol. 33, No. 4. P. 303-312.
2. Burstein N.L. Preservative alteration of corneal permeability in humans and rabbits // IOVS. 1984. Vol. 25, No. 12. P. 1453-1457.
3. Egorov E., Ropo A. Investigators. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma // European Journal of Ophthalmology. 2009. Vol. 19, No. 2. P. 214-222.
4. Erb C., Lanzl I., Seidova S.F., Kimmich F. Preservative-free tafluprost 0.0015 % in the treatment of patients with glaucoma and ocular hypertension // Advances in Therapy. 2011. Vol. 28, No. 7. P. 575-585.
5. Hommer A., Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost // Clinical Ophthalmology. 2011. Vol. 5. P. 623-631.
6. Kashiwagi K., Tsukamoto K., Suzuki M., Tsukahara S. Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes // Journal of Glaucoma. 2002. Vol. 11, No. 1. P. 57-64.
7. Kurashima H., Asai Y., Aihara M. [et al.] Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys // Journal of Glaucoma. 2012. Vol. 21, No. 2. P. 123-128.
8. Madhu C., Rix P., Nguyen T. [et al.] Penetration of natural prostaglandins and their ester prodrugs and analogs across human ocular tissues in vitro // J. Ocul. Pharmacol. Ther. 1998. Vol. 14, No. 5. P. 389-399.
9. Mishima H.K., Masuda K., Kitazawa Y. [et al.] A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study // Archives of Ophthalmology. 1996. Vol. 114, No. 8. P. 929-932.
10. Nakajima T., Matsugi T., Goto W. [et al.] New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents // Biological & Pharmaceutical Bulletin. 2003. Vol. 26, No. 12. P. 1691-1695.
11. Ota T., Murata H., Sugimoto E. [et al.] Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation // IOVS. 2005. Vol. 46, No. 6. P. 2006-2011.
12. Pellinen P., Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost // Ophthalmic Research. 2009. Vol. 41, No. 2. P. 118-122.
13. Sutton A., Gouws P., Ropo A. Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers // Int. J. Clin. Pharmacol. Therap. 2008. Vol. 46, No. 8. P. 400-406.
14. Takagi Y., Nakajima T., Shimazaki A. [et al.] Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug // Experimental eye research. 2004. Vol. 78, No. 4. P. 767-776.
15. Traverso C.E., Ropo A., Papadia M., Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost // J. Ocul. Pharmacol. Ther. 2010. Vol. 26, No. 1. P. 97-104.
16. Uusitalo H., Chen E., Pfeiffer N. [et al.] Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication // Acta ophthalmologica. 2010. Vol. 88, No. 3. P. 329-336.
17. Uusitalo H., Kaarniranta K., Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers // Acta ophthalmologica. 2008. Vol. 242, Suppl. P. 7-13.
18. Uusitalo H., Pillunat L.E., Ropo A., Phase I.I.I.S.I. Efficacy and safety of tafluprost 0.0015 % versus latanoprost 0.005 % eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study // Acta ophthalmologica. 2010. Vol. 88, No. 1. P. 12-19.
Review
For citations:
Petrov S.Yu., Safonova D.M. The pharmacological properties, experimental research and clinical application of tafluprost. Pacific Medical Journal. 2015;(3):11-13. (In Russ.)
Views:
247
Email this article 